Black Diamond Therapeutics (BDTX) Non Operating Income (2019 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Non Operating Income came in at $2.2 million in Q1 2026, up 10.49% YoY from $2.0 million in Q1 2025, and down 10.87% on a QoQ basis from $2.5 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Non Operating Income (2019 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 8 years of Non Operating Income data on file, last reported at $2.2 million in Q1 2026.
- Quarterly Non Operating Income rose 10.49% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.1 million (up 10.55% YoY) and the FY2025 annual result came in at $9.8 million, up 8.13% from the prior year.
- Non Operating Income declined to $2.2 million in Q1 2026, from $2.5 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $3.0 million in Q4 2022 to a low of $172000.0 in Q1 2022.
- A 5-year average of $1.7 million and a median of $2.0 million in 2024 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 1319.72% in 2022, down 58.25% in 2022.
- Tracing BDTX's Non Operating Income over 5 years: stood at $3.0 million in 2022, then slumped by 52.15% to $1.4 million in 2023, then soared by 58.26% to $2.3 million in 2024, then rose by 8.91% to $2.5 million in 2025, then dropped by 10.87% to $2.2 million in 2026.
- The last three Non Operating Income figures came in at $2.2 million (Q1 2026), $2.5 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | 2.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.15 Mn |
| Mar 31, 2026 | 2.22 Mn |
| Dec 31, 2025 | 2.49 Mn |
| Sep 30, 2025 | 2.48 Mn |
| Jun 30, 2025 | 2.86 Mn |
| Mar 31, 2025 | 2.01 Mn |
| Dec 31, 2024 | 2.29 Mn |
| Sep 30, 2024 | 2.57 Mn |
| Jun 30, 2024 | 2.22 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Dec 31, 2023 | 1.45 Mn |
| Sep 30, 2023 | 1.01 Mn |
| Jun 30, 2023 | 880,000.00 |
| Mar 31, 2023 | 686,000.00 |
| Dec 31, 2022 | 3.02 Mn |
| Sep 30, 2022 | 470,000.00 |
| Jun 30, 2022 | 243,000.00 |
| Mar 31, 2022 | 172,000.00 |
| Dec 31, 2021 | 213,000.00 |
| Sep 30, 2021 | 287,000.00 |